Skip to main content

Table 4 Annual CC cases and change from the pre-vaccination situation under the optimal budget allocation

From: Modeling optimal cervical cancer prevention strategies in Nigeria

Sensitivity analyses scenarios

Screening and vaccine coverage constraints

 

20% screening, 95% vaccination

40% screening, 95% vaccination

20% screening, 50% vaccination

Base case (3 doses)

   

Base case—mean treatment costs and one lifetime screening

6.2 (-64%)

6.0 (-66%)

11.4 (-35%)

Prevention cost plus 20% and CIN treatment costs plus 1 SD

6.2 (-64%)

5.9 (-66%)

11.4 (-35%)

Prevention costs minus 20% and CIN treatment costs minus 1 SD

6.2 (-64%)

6.1 (-65%)

11.4 (-35%)

CC treatment costs plus 1 SD

6.2 (-64%)

5.9 (-66%)

11.4 (-35%)

CC treatment costs minus 1 SD

6.2 (-64%)

6.3 (-64%)

11.4 (-35%)

Allow scenarios with two lifetime screenings

6.1 (-65%)

6.0 (-66%)

11.2 (-36%)

Allow scenarios with two or three lifetime screenings

5.9 (-66%)

6.0 (-66%)

11.1 (-37%)

Screening using HPV test

6.2 (-65%)

5.8 (-67%)

11.3 (-35%)

Vaccine duration of protection = 25 years, vaccine efficacy reduced by 20%

7.3 (-58%)

7.1 (-59%)

12.0 (-31%)

Alternative scenario (2 doses) *

   

Base case—mean treatment costs and one lifetime screening

6.2 (-64%)

5.9 (-66%)

11.4 (-35%)

Prevention cost plus 20% and CIN treatment costs plus 1 SD

6.2 (-64%)

5.9 (-66%)

11.4 (-35%)

Prevention costs minus 20% and CIN treatment costs minus 1 SD

6.2 (-64%)

5.9 (-66%)

11.4 (-35%)

CC treatment costs plus 1 SD

6.2 (-64%)

5.9 (-66%)

11.4 (-35%)

CC treatment costs minus 1 SD

6.2 (-64%)

5.9 (-66%)

11.4 (-35%)

Allow scenarios with two lifetime screenings

6.1 (-65%)

5.5 (-68%)

11.2 (-36%)

Allow scenarios with two or three lifetime screenings

5.9 (-66%)

5.3 (-70%)

11.1 (-37%)

Screening using HPV test

6.2 (-65%)

5.8 (-67%)

11.3 (-35%)

Vaccine duration of protection = 25 years, vaccine efficacy reduced by 20%

8.1 (-54%)

7.7 (-56%)

12.3 (-29%)

  1. Sensitivity analyses: budget constraint $2 (~8 times pre-vaccination budget) per woman.
  2. CIN = Cervical intraepithelial neoplasia; CC = Cervical cancer; SD = Standard deviation.
  3. *assume, in the base case, the same efficacy for a three or a two dose vaccine.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us